| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 28 | 2026 | 495 | 4.560 |
Why?
|
| Airway Management | 5 | 2020 | 59 | 2.560 |
Why?
|
| Critical Illness | 5 | 2020 | 332 | 1.700 |
Why?
|
| Prostatectomy | 7 | 2019 | 103 | 1.220 |
Why?
|
| Intensive Care Units | 9 | 2022 | 423 | 1.170 |
Why?
|
| Catheterization, Central Venous | 4 | 2015 | 84 | 1.110 |
Why?
|
| Critical Care | 7 | 2016 | 410 | 1.110 |
Why?
|
| Catheter-Related Infections | 3 | 2015 | 43 | 1.070 |
Why?
|
| Bacteremia | 4 | 2019 | 94 | 0.970 |
Why?
|
| Anesthesiology | 3 | 2023 | 44 | 0.930 |
Why?
|
| Specialization | 2 | 2012 | 82 | 0.740 |
Why?
|
| Communication Disorders | 1 | 2022 | 19 | 0.720 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2022 | 39 | 0.710 |
Why?
|
| Intubation, Intratracheal | 4 | 2019 | 204 | 0.670 |
Why?
|
| Postoperative Complications | 5 | 2021 | 1326 | 0.660 |
Why?
|
| Prostate-Specific Antigen | 10 | 2023 | 84 | 0.640 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2021 | 109 | 0.620 |
Why?
|
| Radiology, Interventional | 1 | 2019 | 31 | 0.600 |
Why?
|
| Humans | 65 | 2026 | 65554 | 0.590 |
Why?
|
| Prostate | 4 | 2024 | 122 | 0.570 |
Why?
|
| Lymph Nodes | 5 | 2026 | 233 | 0.560 |
Why?
|
| Watchful Waiting | 3 | 2025 | 33 | 0.560 |
Why?
|
| Erectile Dysfunction | 2 | 2016 | 28 | 0.540 |
Why?
|
| Male | 46 | 2026 | 31083 | 0.530 |
Why?
|
| Cystectomy | 3 | 2021 | 35 | 0.490 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 272 | 0.480 |
Why?
|
| Urinary Incontinence | 1 | 2016 | 44 | 0.460 |
Why?
|
| Central Venous Catheters | 1 | 2015 | 17 | 0.450 |
Why?
|
| Chlorhexidine | 2 | 2015 | 19 | 0.450 |
Why?
|
| Catheters, Indwelling | 3 | 2010 | 68 | 0.440 |
Why?
|
| Cross Infection | 2 | 2019 | 168 | 0.410 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2026 | 61 | 0.390 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2010 | 59 | 0.380 |
Why?
|
| Patient Care Team | 1 | 2015 | 343 | 0.360 |
Why?
|
| Mass Screening | 2 | 2008 | 706 | 0.360 |
Why?
|
| Spinal Fusion | 1 | 2013 | 157 | 0.340 |
Why?
|
| Lumbar Vertebrae | 1 | 2013 | 175 | 0.340 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2022 | 46 | 0.340 |
Why?
|
| Silver Sulfadiazine | 1 | 2010 | 3 | 0.340 |
Why?
|
| Antimetabolites | 1 | 2010 | 18 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 471 | 0.330 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2010 | 30 | 0.330 |
Why?
|
| Fluorouracil | 1 | 2010 | 70 | 0.330 |
Why?
|
| Oxygen | 3 | 2007 | 325 | 0.320 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2010 | 74 | 0.320 |
Why?
|
| Regression Analysis | 5 | 2015 | 500 | 0.320 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2020 | 115 | 0.310 |
Why?
|
| Hypoxia | 2 | 2012 | 120 | 0.300 |
Why?
|
| Kidney Neoplasms | 3 | 2020 | 175 | 0.290 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2010 | 134 | 0.290 |
Why?
|
| Lymph Node Excision | 4 | 2023 | 46 | 0.290 |
Why?
|
| Equipment Contamination | 1 | 2008 | 34 | 0.290 |
Why?
|
| Middle Aged | 23 | 2023 | 18277 | 0.280 |
Why?
|
| Urethral Obstruction | 1 | 2008 | 6 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2018 | 370 | 0.270 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 5620 | 0.270 |
Why?
|
| Retrospective Studies | 17 | 2023 | 6884 | 0.270 |
Why?
|
| Ejaculation | 1 | 2007 | 9 | 0.260 |
Why?
|
| Genital Diseases, Male | 1 | 2007 | 8 | 0.260 |
Why?
|
| Embolism, Fat | 1 | 2007 | 2 | 0.260 |
Why?
|
| Pelvis | 2 | 2026 | 61 | 0.260 |
Why?
|
| Polymethyl Methacrylate | 1 | 2007 | 15 | 0.260 |
Why?
|
| Bone Cements | 1 | 2007 | 17 | 0.260 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 125 | 0.260 |
Why?
|
| Urology | 2 | 2020 | 46 | 0.260 |
Why?
|
| Neoplasm Metastasis | 2 | 2025 | 221 | 0.250 |
Why?
|
| Aged | 21 | 2023 | 14958 | 0.250 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2006 | 90 | 0.240 |
Why?
|
| Androgen Antagonists | 1 | 2025 | 32 | 0.240 |
Why?
|
| Treatment Outcome | 13 | 2023 | 5822 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 2248 | 0.230 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2025 | 26 | 0.230 |
Why?
|
| Risk Factors | 11 | 2023 | 5441 | 0.230 |
Why?
|
| Lung Diseases | 1 | 2007 | 183 | 0.230 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 92 | 0.220 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 546 | 0.220 |
Why?
|
| Consensus | 2 | 2024 | 185 | 0.220 |
Why?
|
| Positron-Emission Tomography | 3 | 2023 | 227 | 0.220 |
Why?
|
| Staphylococcal Infections | 2 | 2017 | 137 | 0.220 |
Why?
|
| Adult | 20 | 2023 | 17417 | 0.210 |
Why?
|
| Nuclear Medicine | 1 | 2023 | 9 | 0.200 |
Why?
|
| Cryosurgery | 1 | 2023 | 28 | 0.200 |
Why?
|
| Radiotherapy Dosage | 1 | 2022 | 87 | 0.180 |
Why?
|
| Comorbidity | 3 | 2013 | 1126 | 0.180 |
Why?
|
| Contrast Media | 1 | 2024 | 433 | 0.180 |
Why?
|
| Logistic Models | 8 | 2017 | 1282 | 0.170 |
Why?
|
| Radiology | 3 | 2020 | 262 | 0.170 |
Why?
|
| Spinal Cord Ischemia | 1 | 2020 | 15 | 0.160 |
Why?
|
| Fungemia | 1 | 2019 | 6 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 68 | 0.150 |
Why?
|
| Sarcopenia | 1 | 2020 | 28 | 0.150 |
Why?
|
| Drainage | 1 | 2020 | 155 | 0.150 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 866 | 0.150 |
Why?
|
| Aortic Aneurysm | 1 | 2020 | 82 | 0.150 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 51 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 102 | 0.150 |
Why?
|
| Laryngoscopy | 1 | 2019 | 62 | 0.150 |
Why?
|
| Female | 17 | 2021 | 34131 | 0.140 |
Why?
|
| Risk Assessment | 5 | 2023 | 2101 | 0.140 |
Why?
|
| Quality Assurance, Health Care | 1 | 2020 | 260 | 0.140 |
Why?
|
| Perioperative Care | 2 | 2010 | 87 | 0.140 |
Why?
|
| Incidence | 3 | 2023 | 1410 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 210 | 0.130 |
Why?
|
| Anesthesia, Conduction | 1 | 2017 | 11 | 0.130 |
Why?
|
| Subclavian Artery | 1 | 2017 | 26 | 0.130 |
Why?
|
| Follow-Up Studies | 5 | 2014 | 2510 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 2 | 2016 | 144 | 0.130 |
Why?
|
| United States | 5 | 2019 | 8131 | 0.130 |
Why?
|
| Predictive Value of Tests | 5 | 2023 | 1114 | 0.130 |
Why?
|
| Candidemia | 1 | 2017 | 9 | 0.130 |
Why?
|
| Europe | 4 | 2023 | 202 | 0.130 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2017 | 25 | 0.130 |
Why?
|
| Communication | 1 | 2022 | 593 | 0.130 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2007 | 9 | 0.130 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 30 | 0.130 |
Why?
|
| Early Ambulation | 1 | 2016 | 10 | 0.130 |
Why?
|
| Pseudomonas Infections | 1 | 2017 | 54 | 0.130 |
Why?
|
| Spinal Cord Compression | 2 | 2007 | 30 | 0.120 |
Why?
|
| Physical Therapy Modalities | 1 | 2016 | 46 | 0.120 |
Why?
|
| Inpatients | 1 | 2019 | 311 | 0.120 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2016 | 7 | 0.120 |
Why?
|
| Germany | 3 | 2016 | 54 | 0.120 |
Why?
|
| Patient Care Planning | 1 | 2016 | 83 | 0.120 |
Why?
|
| Disease Management | 1 | 2017 | 237 | 0.120 |
Why?
|
| Hand Hygiene | 1 | 2015 | 10 | 0.110 |
Why?
|
| Staphylococcus | 1 | 2015 | 17 | 0.110 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 116 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 85 | 0.110 |
Why?
|
| Single-Blind Method | 2 | 2016 | 142 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 107 | 0.110 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 195 | 0.110 |
Why?
|
| Blood Component Transfusion | 1 | 2013 | 11 | 0.100 |
Why?
|
| Hospital Charges | 1 | 2013 | 22 | 0.100 |
Why?
|
| Quality of Life | 1 | 2021 | 1270 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2014 | 145 | 0.100 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 626 | 0.100 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 525 | 0.100 |
Why?
|
| Intubation | 1 | 2012 | 10 | 0.100 |
Why?
|
| Demography | 1 | 2013 | 180 | 0.100 |
Why?
|
| Laryngoscopes | 1 | 2012 | 22 | 0.100 |
Why?
|
| Hypotension | 1 | 2012 | 50 | 0.090 |
Why?
|
| Muscle, Skeletal | 2 | 2007 | 766 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 193 | 0.090 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 2 | 2022 | 8 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 272 | 0.090 |
Why?
|
| Dipeptides | 2 | 2022 | 68 | 0.090 |
Why?
|
| Prevalence | 2 | 2013 | 1441 | 0.090 |
Why?
|
| Robotic Surgical Procedures | 1 | 2014 | 164 | 0.080 |
Why?
|
| Colony Count, Microbial | 1 | 2010 | 60 | 0.080 |
Why?
|
| Image-Guided Biopsy | 2 | 2021 | 50 | 0.080 |
Why?
|
| Respiration, Artificial | 1 | 2013 | 299 | 0.080 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2010 | 29 | 0.080 |
Why?
|
| Antisepsis | 1 | 2010 | 7 | 0.080 |
Why?
|
| Delphi Technique | 2 | 2021 | 111 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 93 | 0.080 |
Why?
|
| Radiopharmaceuticals | 2 | 2022 | 192 | 0.080 |
Why?
|
| Gram-Positive Bacteria | 1 | 2010 | 36 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2023 | 3355 | 0.080 |
Why?
|
| Gallium Isotopes | 2 | 2019 | 2 | 0.080 |
Why?
|
| Edetic Acid | 2 | 2019 | 24 | 0.080 |
Why?
|
| Gallium Radioisotopes | 2 | 2019 | 15 | 0.080 |
Why?
|
| Length of Stay | 1 | 2013 | 831 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2010 | 97 | 0.080 |
Why?
|
| Patient Discharge | 1 | 2013 | 522 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2023 | 94 | 0.070 |
Why?
|
| Oligopeptides | 2 | 2019 | 135 | 0.070 |
Why?
|
| Ohio | 1 | 2008 | 24 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2010 | 1156 | 0.070 |
Why?
|
| Catheterization, Peripheral | 1 | 2008 | 51 | 0.070 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2007 | 26 | 0.070 |
Why?
|
| Hypovolemia | 1 | 2007 | 17 | 0.070 |
Why?
|
| Age Distribution | 1 | 2008 | 259 | 0.070 |
Why?
|
| Hand Strength | 1 | 2007 | 34 | 0.060 |
Why?
|
| Equipment Design | 1 | 2008 | 362 | 0.060 |
Why?
|
| Immobilization | 1 | 2007 | 14 | 0.060 |
Why?
|
| Prognosis | 3 | 2021 | 1793 | 0.060 |
Why?
|
| Neuromuscular Agents | 1 | 2007 | 16 | 0.060 |
Why?
|
| Carbon Dioxide | 1 | 2007 | 86 | 0.060 |
Why?
|
| Veins | 1 | 2007 | 64 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2007 | 213 | 0.060 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2006 | 3 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2008 | 589 | 0.060 |
Why?
|
| Hypothermia | 1 | 2006 | 17 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 741 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2014 | 2632 | 0.060 |
Why?
|
| Hypnotics and Sedatives | 1 | 2007 | 66 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2782 | 0.060 |
Why?
|
| Nomograms | 1 | 2006 | 19 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2007 | 124 | 0.060 |
Why?
|
| Transfusion Reaction | 1 | 2006 | 45 | 0.060 |
Why?
|
| Hemodynamics | 1 | 2007 | 257 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 286 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 137 | 0.060 |
Why?
|
| Cervical Vertebrae | 1 | 2007 | 120 | 0.060 |
Why?
|
| Obesity, Morbid | 1 | 2007 | 95 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2017 | 94 | 0.060 |
Why?
|
| Time Factors | 4 | 2021 | 3788 | 0.060 |
Why?
|
| Emergencies | 1 | 2005 | 123 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 938 | 0.050 |
Why?
|
| Pain | 1 | 2007 | 403 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 1701 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 739 | 0.050 |
Why?
|
| Adolescent | 3 | 2015 | 6377 | 0.050 |
Why?
|
| Biopsy | 3 | 2014 | 457 | 0.050 |
Why?
|
| Disease Progression | 1 | 2008 | 1218 | 0.050 |
Why?
|
| Norway | 1 | 2023 | 23 | 0.050 |
Why?
|
| Middle East | 1 | 2023 | 13 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2023 | 34 | 0.050 |
Why?
|
| Journal Impact Factor | 1 | 2023 | 26 | 0.050 |
Why?
|
| Obesity | 1 | 2011 | 1269 | 0.050 |
Why?
|
| Molecular Imaging | 1 | 2023 | 53 | 0.050 |
Why?
|
| Age Factors | 1 | 2007 | 1592 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1575 | 0.050 |
Why?
|
| Survival Rate | 2 | 2015 | 861 | 0.050 |
Why?
|
| Precision Medicine | 1 | 2023 | 127 | 0.050 |
Why?
|
| Post-Dural Puncture Headache | 1 | 2020 | 5 | 0.040 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2020 | 9 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 37 | 0.040 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2020 | 17 | 0.040 |
Why?
|
| Exercise | 1 | 2007 | 964 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2020 | 94 | 0.040 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 95 | 0.040 |
Why?
|
| Cisplatin | 1 | 2020 | 149 | 0.040 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2020 | 110 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2020 | 272 | 0.030 |
Why?
|
| Blood Culture | 1 | 2017 | 10 | 0.030 |
Why?
|
| APACHE | 1 | 2017 | 43 | 0.030 |
Why?
|
| Posture | 1 | 2017 | 128 | 0.030 |
Why?
|
| Austria | 1 | 2016 | 8 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2007 | 150 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 801 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 131 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 72 | 0.030 |
Why?
|
| Soft Tissue Infections | 1 | 2017 | 48 | 0.030 |
Why?
|
| Hospital Mortality | 2 | 2011 | 879 | 0.030 |
Why?
|
| Oncology Nursing | 1 | 2016 | 16 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 76 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 90 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 375 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 694 | 0.030 |
Why?
|
| Stents | 1 | 2020 | 502 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 409 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2017 | 96 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2007 | 468 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 161 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1018 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2016 | 113 | 0.030 |
Why?
|
| Documentation | 1 | 2016 | 132 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 734 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1473 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 313 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 682 | 0.030 |
Why?
|
| Kallikreins | 1 | 2014 | 9 | 0.030 |
Why?
|
| Research Design | 1 | 2016 | 585 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 4831 | 0.020 |
Why?
|
| Decision Making | 1 | 2017 | 420 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 612 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 490 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 1049 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2010 | 51 | 0.020 |
Why?
|
| Rifampin | 1 | 2010 | 25 | 0.020 |
Why?
|
| Minocycline | 1 | 2010 | 28 | 0.020 |
Why?
|
| Bacterial Adhesion | 1 | 2010 | 64 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 156 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 764 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 154 | 0.020 |
Why?
|
| Lower Body Negative Pressure | 1 | 2007 | 8 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2007 | 47 | 0.020 |
Why?
|
| Blood Volume | 1 | 2007 | 40 | 0.020 |
Why?
|
| Partial Pressure | 1 | 2007 | 9 | 0.020 |
Why?
|
| Physical Examination | 1 | 2007 | 110 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 2007 | 83 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2007 | 75 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 416 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2007 | 140 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 122 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 52 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2010 | 1451 | 0.010 |
Why?
|
| Temperature | 1 | 2007 | 316 | 0.010 |
Why?
|
| Heart Rate | 1 | 2007 | 331 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2007 | 338 | 0.010 |
Why?
|
| ROC Curve | 1 | 2006 | 295 | 0.010 |
Why?
|
| Infant | 1 | 2010 | 1718 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2007 | 526 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2007 | 301 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2010 | 2077 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2007 | 558 | 0.010 |
Why?
|
| Skin | 1 | 2007 | 424 | 0.010 |
Why?
|
| Massachusetts | 1 | 2010 | 2149 | 0.010 |
Why?
|
| Child | 1 | 2010 | 4681 | 0.010 |
Why?
|